<?xml version="1.0"?>
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20190208//EN"
       "JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.4" xml:lang="en">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">Medical Radiology and radiation safety</journal-id>
   <journal-title-group>
    <journal-title xml:lang="en">Medical Radiology and radiation safety</journal-title>
    <trans-title-group xml:lang="ru">
     <trans-title>Медицинская радиология и радиационная безопасность</trans-title>
    </trans-title-group>
   </journal-title-group>
   <issn publication-format="print">1024-6177</issn>
   <issn publication-format="online">2618-9615</issn>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">30607</article-id>
   <article-id pub-id-type="doi">10.12737/1024-6177-2019-64-5-58-68</article-id>
   <article-categories>
    <subj-group subj-group-type="toc-heading" xml:lang="ru">
     <subject>Обзор</subject>
    </subj-group>
    <subj-group subj-group-type="toc-heading" xml:lang="en">
     <subject>Review</subject>
    </subj-group>
    <subj-group>
     <subject>Обзор</subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">Actual Problems and Perspectives of the Application of Nuclear Medicine Techniques in the Diagnostic and Treatment of Hepatocellular Carcinoma: Analytical Review</article-title>
    <trans-title-group xml:lang="ru">
     <trans-title>Актуальные проблемы и перспективы применения методов ядерной медицины в диагностике и лечении гепатоцеллюлярной карциномы: аналитический обзор</trans-title>
    </trans-title-group>
   </title-group>
   <contrib-group content-type="authors">
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Бушманов</surname>
       <given-names>А. Ю.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Bushmanov</surname>
       <given-names>A. Yu.</given-names>
      </name>
     </name-alternatives>
     <bio xml:lang="ru">
      <p>доктор медицинских наук;</p>
     </bio>
     <bio xml:lang="en">
      <p>doctor of medical sciences;</p>
     </bio>
     <xref ref-type="aff" rid="aff-1"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Клементьева</surname>
       <given-names>О. Е.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Klement'eva</surname>
       <given-names>O. E.</given-names>
      </name>
     </name-alternatives>
     <bio xml:lang="ru">
      <p>кандидат биологических наук;</p>
     </bio>
     <bio xml:lang="en">
      <p>candidate of sciences in biology;</p>
     </bio>
     <xref ref-type="aff" rid="aff-2"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Лабушкина</surname>
       <given-names>А. А.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Labushkina</surname>
       <given-names>A. A.</given-names>
      </name>
     </name-alternatives>
     <bio xml:lang="ru">
      <p>кандидат медицинских наук;</p>
     </bio>
     <bio xml:lang="en">
      <p>candidate of medical sciences;</p>
     </bio>
     <xref ref-type="aff" rid="aff-3"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Тултаев</surname>
       <given-names>А. В.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Tultaev</surname>
       <given-names>A. V.</given-names>
      </name>
     </name-alternatives>
     <bio xml:lang="ru">
      <p>кандидат технических наук;</p>
     </bio>
     <bio xml:lang="en">
      <p>candidate of technical sciences;</p>
     </bio>
     <xref ref-type="aff" rid="aff-4"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Корсунский</surname>
       <given-names>В. Н.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Korsunskiy</surname>
       <given-names>V. N.</given-names>
      </name>
     </name-alternatives>
     <bio xml:lang="ru">
      <p>доктор медицинских наук;</p>
     </bio>
     <bio xml:lang="en">
      <p>doctor of medical sciences;</p>
     </bio>
     <xref ref-type="aff" rid="aff-5"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Кузнецова</surname>
       <given-names>О. В.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Kuznetsova</surname>
       <given-names>O. V.</given-names>
      </name>
     </name-alternatives>
     <bio xml:lang="ru">
      <p>кандидат биологических наук;</p>
     </bio>
     <bio xml:lang="en">
      <p>candidate of sciences in biology;</p>
     </bio>
     <xref ref-type="aff" rid="aff-6"/>
    </contrib>
   </contrib-group>
   <aff-alternatives id="aff-1">
    <aff>
     <institution xml:lang="ru">Федеральный медицинский биофизический центр им. А.И. Бурназяна ФМБА России</institution>
     <city>Москва</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">A.I. Burnasyan Federal Medical Biophysical Center of FMBA</institution>
     <city>Moscow</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-2">
    <aff>
     <institution xml:lang="ru">Федеральный медицинский биофизический центр им. А.И. Бурназяна ФМБА России</institution>
     <city>Москва</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">A.I. Burnasyan Federal Medical Biophysical Center of FMBA</institution>
     <city>Moscow</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-3">
    <aff>
     <institution xml:lang="ru">Федеральный медицинский биофизический центр им. А.И. Бурназяна ФМБА России</institution>
     <city>Москва</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">A.I. Burnasyan Federal Medical Biophysical Center of FMBA</institution>
     <city>Moscow</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-4">
    <aff>
     <institution xml:lang="ru">Федеральный медицинский биофизический центр им. А.И. Бурназяна ФМБА России</institution>
     <city>Москва</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">A.I. Burnasyan Federal Medical Biophysical Center of FMBA</institution>
     <city>Moscow</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-5">
    <aff>
     <institution xml:lang="ru">Федеральный медицинский биофизический центр им. А.И. Бурназяна ФМБА России</institution>
     <city>Москва</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">A.I. Burnasyan Federal Medical Biophysical Center of FMBA</institution>
     <city>Moscow</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <aff-alternatives id="aff-6">
    <aff>
     <institution xml:lang="ru">Федеральный медицинский биофизический центр им. А.И. Бурназяна ФМБА России</institution>
     <city>Москва</city>
     <country>Россия</country>
    </aff>
    <aff>
     <institution xml:lang="en">A.I. Burnasyan Federal Medical Biophysical Center of FMBA</institution>
     <city>Moscow</city>
     <country>Russian Federation</country>
    </aff>
   </aff-alternatives>
   <volume>64</volume>
   <issue>5</issue>
   <fpage>58</fpage>
   <lpage>68</lpage>
   <self-uri xlink:href="https://zh-szf.ru/en/nauka/article/30607/view">https://zh-szf.ru/en/nauka/article/30607/view</self-uri>
   <abstract xml:lang="ru">
    <p>В представленном обзоре публикаций, вместе с кратким анализом заболеваемости, факторов риска возникновения и методов диагностики гепатоцеллюлярной карциномы (ГЦК), обозначены современные проблемы и перспективы применения методов ядерной медицины в диагностике и лечении данного заболевания. Гепатоцеллюлярная карцинома представляет собой одну из наиболее распространенных злокачественных опухолей печени и характеризуется быстро прогрессирующим течением с неблагоприятным жизненным прогнозом. Разнообразие клинических проявлений заболевания создает определенные трудности в ранней диагностике ГЦК. Несмотря на то, что для скрининга ГЦК наиболее часто используется определение уровня альфа-фетопротеина (АФП), ультразвуковое исследование (УЗИ), КТ с болюсным контрастированием и МРТ, важное значение в клинической практике имеет опыт применения радионуклидных визуализирующих методов диагностики, включая позитронную эмиссионную томографию (ПЭТ), которые, не являясь основным методом первичной диагностики ГЦК, тем не менее подтвердили свою актуальность в проведении дифференциальной диагностики между доброкачественной опухолью и метастазом при неясных диагностических данных, а также в процессе мониторинга лечения и в диагностике отдаленных метастазов. Вопросы концепции в определении лечебной стратегии у пациентов с ГЦК, в зависимости от стадирования заболевания, перспективы оптимизации стратегий лечения и традиционные методы лечения ГЦК подробно и глубоко освещены в разнообразных публикациях, включая публикации отечественных авторов. Исходя из этого, авторы статьи ограничились лишь кратким анализом применения методов эмболизации и лучевой терапии в лечении ГЦК, активное развитие которой в последнее десятилетие, а также перспективные ранние результаты лечения, предполагают, что лучевая терапия может рассматриваться как основной метод лечения ГЦК, наряду с другими традиционными методами. &#13;
Дальнейшее изучение и развитие радионуклидных методов диагностики и терапии ГЦК, а также поиск и изучение новых РФП для диагностики и регионарной внутриартериальной радионуклидной терапии является одним из перспективных направлений в современных подходах к диагностике и лечению ГЦК.</p>
   </abstract>
   <trans-abstract xml:lang="en">
    <p>In the presented review of publications, together with a brief analysis of the incidence, risk factors for the occurrence and methods of diagnosis of hepatocellular carcinoma (HCC), current problems and prospects for the application of nuclear medicine methods in the diagnosis and treatment of this disease are indicated. Hepatocellular carcinoma is one of the most common malignant tumors of the liver and is characterized by a rapidly progressing course with an unfavorable life expectancy. A variety of clinical manifestations of the disease creates certain difficulties in the early diagnosis of HCC. Although HCC screening is most commonly used to determine the level of alpha-fetoprotein (AFP), ultrasound (US), bolus CT and MRI, experience in the use of radionuclide imaging diagnostics, including positron emission tomography, is important in clinical practice (PET), which, not being the main method of primary diagnosis of HCC, however, confirmed their relevance in the differential diagnosis between a benign tumor and metastasis with unclear diagnostic data, as well as in the process of monitoring treatment and in the diagnosis of distant metastases. Conceptual issues in determining the treatment strategy of patients with HCC, depending on the staging of the disease, the prospects for optimizing treatment strategies and traditional methods of treating HCC in detail and in depth are covered in various publications, including publications of domestic authors. Based on this, the authors of the article limited themselves to a brief analysis of the use of embolization and radiation therapy methods for treating HCC, the active development of which in the last decade, as well as promising early results of treatment, suggest that radiation therapy can be considered as the main treatment method for HCC traditional methods. &#13;
Further study and development of radionuclide methods for the diagnosis and therapy of HCC, as well as the search and study of new radiopharmaceuticals for diagnosis and regional intraarterial radiotherapy is one of the promising directions in modern approaches to the diagnosis and treatment of HCC.</p>
   </trans-abstract>
   <kwd-group xml:lang="ru">
    <kwd>гепатоцеллюлярная карцинома</kwd>
    <kwd>ядерная медицина</kwd>
    <kwd>радиоэмболизация</kwd>
    <kwd>химиоэмболизация</kwd>
    <kwd>липиодол</kwd>
    <kwd>сорафениб</kwd>
    <kwd>внутриартериальная радионуклидная терапия</kwd>
   </kwd-group>
   <kwd-group xml:lang="en">
    <kwd>hepatocellular carcinoma</kwd>
    <kwd>nuclear medicine</kwd>
    <kwd>radioembolization</kwd>
    <kwd>chemoembolization</kwd>
    <kwd>lipiodol</kwd>
    <kwd>sorafenib</kwd>
    <kwd>intraarterial radionuclide therapy</kwd>
   </kwd-group>
  </article-meta>
 </front>
 <body>
  <p></p>
 </body>
 <back>
  <ref-list>
   <ref id="B1">
    <label>1.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA. Cancer J Clin. 2005;55:74-108.</mixed-citation>
     <mixed-citation xml:lang="en">Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA. Cancer J Clin. 2005;55:74-108.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B2">
    <label>2.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Sorinson SN. Viral hepatitis - St. Petersburg: Teza, 1998, 331 p. (Russian).</mixed-citation>
     <mixed-citation xml:lang="en">Sorinson SN. Viral hepatitis - St. Petersburg: Teza, 1998, 331 p. (Russian).</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B3">
    <label>3.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Patyutko Yu. I. Epidemiology, molecular biology and prevention of liver cancer. In: Surgical treatment of malignant liver tumors - Moscow: Practical medicine. 2005, 312 p. (Russian).</mixed-citation>
     <mixed-citation xml:lang="en">Patyutko Yu. I. Epidemiology, molecular biology and prevention of liver cancer. In: Surgical treatment of malignant liver tumors - Moscow: Practical medicine. 2005, 312 p. (Russian).</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B4">
    <label>4.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">World Health Organization, Office of Health Communications and Public Relations. Cancer. In: WHO fact sheet, no 297. - Geneva: World Health Organization. 2006:4</mixed-citation>
     <mixed-citation xml:lang="en">World Health Organization, Office of Health Communications and Public Relations. Cancer. In: WHO fact sheet, no 297. - Geneva: World Health Organization. 2006:4</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B5">
    <label>5.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Bosch F.X, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterol. 2004:127(5, Suppl 1):5-16.</mixed-citation>
     <mixed-citation xml:lang="en">Bosch F.X, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterol. 2004:127(5, Suppl 1):5-16.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B6">
    <label>6.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Montalto G, Cervello M, Giannitrapani L, et al. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci. 2002:963:13-20.</mixed-citation>
     <mixed-citation xml:lang="en">Montalto G, Cervello M, Giannitrapani L, et al. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci. 2002:963:13-20.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B7">
    <label>7.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Kurien T, Thyagarajan SP, Jeyaseelan L, et al. Community prevalence of hepatitis B infection and modes of transmission in Tamil Nadu, India. Indian J Med Res. 2005;121(5):670-5.</mixed-citation>
     <mixed-citation xml:lang="en">Kurien T, Thyagarajan SP, Jeyaseelan L, et al. Community prevalence of hepatitis B infection and modes of transmission in Tamil Nadu, India. Indian J Med Res. 2005;121(5):670-5.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B8">
    <label>8.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-17.</mixed-citation>
     <mixed-citation xml:lang="en">Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-17.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B9">
    <label>9.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Lupberger J, Hildt E. Hepatitus B virus-induced oncogenesis. World J Gastroenterol. 2007;13(1):74-81.</mixed-citation>
     <mixed-citation xml:lang="en">Lupberger J, Hildt E. Hepatitus B virus-induced oncogenesis. World J Gastroenterol. 2007;13(1):74-81.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B10">
    <label>10.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Breder VV, Bisovskaya YV. Hepatocellular carcinoma: the experience of the Russian Cancer Center. 4th International Scientific and Practical Conference «White Nights of Hepatology 2012». 2012. (Russian).</mixed-citation>
     <mixed-citation xml:lang="en">Breder VV, Bisovskaya YV. Hepatocellular carcinoma: the experience of the Russian Cancer Center. 4th International Scientific and Practical Conference «White Nights of Hepatology 2012». 2012. (Russian).</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B11">
    <label>11.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Ivashkin VT, Morozova MA, Maevskaya MV, et al. Risk factors for hepatocellular carcinoma. Russian Journal of Gastroenterology, Hepatology and Coloproctology. 2009;1:4-15. (Russian).</mixed-citation>
     <mixed-citation xml:lang="en">Ivashkin VT, Morozova MA, Maevskaya MV, et al. Risk factors for hepatocellular carcinoma. Russian Journal of Gastroenterology, Hepatology and Coloproctology. 2009;1:4-15. (Russian).</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B12">
    <label>12.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Patutko YI, et al. Principles of early diagnosis and screening of HCC. The 2nd International Scientific and Practical Conference «White Nights of Hepatology 2010». 2010. (Russian).</mixed-citation>
     <mixed-citation xml:lang="en">Patutko YI, et al. Principles of early diagnosis and screening of HCC. The 2nd International Scientific and Practical Conference «White Nights of Hepatology 2010». 2010. (Russian).</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B13">
    <label>13.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Ivashkin VT, Pavlov ChS. Liver tumors, precancerous diseases and conditions. Hepatocellular carcinoma. Rational pharmacotherapy of diseases of the digestive system. - Moscow: Litterra. 2003, P. 459-64. (Russian).</mixed-citation>
     <mixed-citation xml:lang="en">Ivashkin VT, Pavlov ChS. Liver tumors, precancerous diseases and conditions. Hepatocellular carcinoma. Rational pharmacotherapy of diseases of the digestive system. - Moscow: Litterra. 2003, P. 459-64. (Russian).</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B14">
    <label>14.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Malignant neoplasms in Russia in 2013 (morbidity and mortality) Ed. A.D. Caprin, V.V. Starinskoy, G.V. Petrov.  Moscow. 2015, 250 p. (Russian).</mixed-citation>
     <mixed-citation xml:lang="en">Malignant neoplasms in Russia in 2013 (morbidity and mortality) Ed. A.D. Caprin, V.V. Starinskoy, G.V. Petrov.  Moscow. 2015, 250 p. (Russian).</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B15">
    <label>15.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Maev IV, Dicheva DT, Zhilyaev EV, et al. Difficulties in diagnosing hepatocellular carcinoma. Consilium Med. 2010;8:63-6. (Russian).</mixed-citation>
     <mixed-citation xml:lang="en">Maev IV, Dicheva DT, Zhilyaev EV, et al. Difficulties in diagnosing hepatocellular carcinoma. Consilium Med. 2010;8:63-6. (Russian).</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B16">
    <label>16.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Trevisani F, D’Intino P.E, Morselli-Labate A.M, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001, 34:570-5.</mixed-citation>
     <mixed-citation xml:lang="en">Trevisani F, D’Intino P.E, Morselli-Labate A.M, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001, 34:570-5.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B17">
    <label>17.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Shen Q, Fan J, Yang XR, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13:817-26.</mixed-citation>
     <mixed-citation xml:lang="en">Shen Q, Fan J, Yang XR, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13:817-26.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B18">
    <label>18.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Colli Al. Accurancy of ultrasonography, spiral CT, magnetic resonance and alpha-fetoprotein in diagnosing hepatocellular carcinoma; a systematic review. Am J Gastroenterol. 2006;101(3):513-23.</mixed-citation>
     <mixed-citation xml:lang="en">Colli Al. Accurancy of ultrasonography, spiral CT, magnetic resonance and alpha-fetoprotein in diagnosing hepatocellular carcinoma; a systematic review. Am J Gastroenterol. 2006;101(3):513-23.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B19">
    <label>19.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Miller WJ, Federle MP, Campbell WL. Diagnosis and staging of hepatocellular carcinoma: comparison of CT and sonography in 36 liver transplantation patients. Am. J. Roentgenol, 1991;157:303-6.</mixed-citation>
     <mixed-citation xml:lang="en">Miller WJ, Federle MP, Campbell WL. Diagnosis and staging of hepatocellular carcinoma: comparison of CT and sonography in 36 liver transplantation patients. Am. J. Roentgenol, 1991;157:303-6.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B20">
    <label>20.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Lim JH, et al. Detection of hepatocellular carcinoma: value ofadding delayed phase to dual-phase helical CT. Am J Roentgenol. 2002;179(1):67-73.</mixed-citation>
     <mixed-citation xml:lang="en">Lim JH, et al. Detection of hepatocellular carcinoma: value ofadding delayed phase to dual-phase helical CT. Am J Roentgenol. 2002;179(1):67-73.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B21">
    <label>21.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Burrel M, et al. MRI angiography in superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatol. 2003;38(4):1034-42.</mixed-citation>
     <mixed-citation xml:lang="en">Burrel M, et al. MRI angiography in superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatol. 2003;38(4):1034-42.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B22">
    <label>22.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Radionuclide diagnostics for practical doctors. Ed. YuB. Lishmanov, V.I. Chernov. Tomsk: STT. 2004. (Russian).</mixed-citation>
     <mixed-citation xml:lang="en">Radionuclide diagnostics for practical doctors. Ed. YuB. Lishmanov, V.I. Chernov. Tomsk: STT. 2004. (Russian).</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B23">
    <label>23.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Khubutia MSh, Kudryashova NE, Sinyakova OG, et al. The use of radioisotope techniques of research in the preparation of patients for liver transplantation and in the postoperative period. Trasplantology. 2010;1:5-11. (Russian).</mixed-citation>
     <mixed-citation xml:lang="en">Khubutia MSh, Kudryashova NE, Sinyakova OG, et al. The use of radioisotope techniques of research in the preparation of patients for liver transplantation and in the postoperative period. Trasplantology. 2010;1:5-11. (Russian).</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B24">
    <label>24.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Jalmukashev UK, Tazhedinov IT. Quantitative evaluation of the results of two-indicator radionuclide studies in focal lesions of the liver. Med Radiology and Radiation Safety. 2000;45(6):27-32. (Russian).</mixed-citation>
     <mixed-citation xml:lang="en">Jalmukashev UK, Tazhedinov IT. Quantitative evaluation of the results of two-indicator radionuclide studies in focal lesions of the liver. Med Radiology and Radiation Safety. 2000;45(6):27-32. (Russian).</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B25">
    <label>25.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Smolyarchuk MYa, Davydov GA, Efimov ON. Radionuclide studies in the study of kidney function and diagnosis of metastatic skeletal lesions in oncourologic patients. - In the collection. «Materials of the 2nd All-Russian National Congress on Radiation Diagnostics and Therapy”, Moscow. 2008:268-9. (Russian).</mixed-citation>
     <mixed-citation xml:lang="en">Smolyarchuk MYa, Davydov GA, Efimov ON. Radionuclide studies in the study of kidney function and diagnosis of metastatic skeletal lesions in oncourologic patients. - In the collection. «Materials of the 2nd All-Russian National Congress on Radiation Diagnostics and Therapy”, Moscow. 2008:268-9. (Russian).</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B26">
    <label>26.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Delbeke D, Martin WH, Sandler MP, et al. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg, 1998;133:510-6.</mixed-citation>
     <mixed-citation xml:lang="en">Delbeke D, Martin WH, Sandler MP, et al. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg, 1998;133:510-6.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B27">
    <label>27.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Trufanov GE. Radiation diagnosis of liver diseases (MRI, CT, ultrasound, SPECT and PET). Moscow: GEOTAR-Media. 2008. 263p. (Russian).</mixed-citation>
     <mixed-citation xml:lang="en">Trufanov GE. Radiation diagnosis of liver diseases (MRI, CT, ultrasound, SPECT and PET). Moscow: GEOTAR-Media. 2008. 263p. (Russian).</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B28">
    <label>28.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Khan MA, Combs CS, Brunt EM, et al. PET scanning in the evaluation of hepatocellular carcinoma. J Hepatol. 2000;32:792-7.</mixed-citation>
     <mixed-citation xml:lang="en">Khan MA, Combs CS, Brunt EM, et al. PET scanning in the evaluation of hepatocellular carcinoma. J Hepatol. 2000;32:792-7.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B29">
    <label>29.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Saiton S, Koida I, Ikeda K, et al. Diagnosis and follow-up of small hepatocellular carcinoma with seledive intraarterial digital subtraction angiography. Hepatol. 1993;17:1003-7.</mixed-citation>
     <mixed-citation xml:lang="en">Saiton S, Koida I, Ikeda K, et al. Diagnosis and follow-up of small hepatocellular carcinoma with seledive intraarterial digital subtraction angiography. Hepatol. 1993;17:1003-7.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B30">
    <label>30.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Takayasu K, Moriyama N, Muramatsu Y, et al. The diagnosis of small hepatocellular carcinomas: efficacy of various imaging procedures in 100 patients. Amer J Roentgenol. 1990;155:49-54.</mixed-citation>
     <mixed-citation xml:lang="en">Takayasu K, Moriyama N, Muramatsu Y, et al. The diagnosis of small hepatocellular carcinomas: efficacy of various imaging procedures in 100 patients. Amer J Roentgenol. 1990;155:49-54.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B31">
    <label>31.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Tamm EP, Rabushka LS, Fishman EK, et al. Intrahepatic extramedullary hematopoiesis mimicking hemangioma on Tc-99m red blood cell SPECT examination. Clin Imag. 1995;19:88-91.</mixed-citation>
     <mixed-citation xml:lang="en">Tamm EP, Rabushka LS, Fishman EK, et al. Intrahepatic extramedullary hematopoiesis mimicking hemangioma on Tc-99m red blood cell SPECT examination. Clin Imag. 1995;19:88-91.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B32">
    <label>32.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Trends and practices in diagnosis and treatment of hepatocellular carcinoma. STI/PUB/1446. IAEA. 2010</mixed-citation>
     <mixed-citation xml:lang="en">Trends and practices in diagnosis and treatment of hepatocellular carcinoma. STI/PUB/1446. IAEA. 2010</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B33">
    <label>33.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Breder VV, Patyutko YuI, Peregudova MV, Kosyrev VYu, Kudashkin NE, Romanova KA, Laktionov KK. Comparative analysis of modern hepatocellular cancer staging systems - TNM / AJCC, CUPI, CLIP and BCLC in Russian oncology. Malignant Tumors. 2016:2:28-36. (Russian).</mixed-citation>
     <mixed-citation xml:lang="en">Breder VV, Patyutko YuI, Peregudova MV, Kosyrev VYu, Kudashkin NE, Romanova KA, Laktionov KK. Comparative analysis of modern hepatocellular cancer staging systems - TNM / AJCC, CUPI, CLIP and BCLC in Russian oncology. Malignant Tumors. 2016:2:28-36. (Russian).</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B34">
    <label>34.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Breder VV, Laktionov KP. Hepatocellular carcinoma of the intermediate stage. BCLC B - official recommendations, as a basic treatment strategy and benchmark in assessing the effectiveness of new approaches. Malignant Tumors. 2016;4(Special issue 1):29-35. (Russian).</mixed-citation>
     <mixed-citation xml:lang="en">Breder VV, Laktionov KP. Hepatocellular carcinoma of the intermediate stage. BCLC B - official recommendations, as a basic treatment strategy and benchmark in assessing the effectiveness of new approaches. Malignant Tumors. 2016;4(Special issue 1):29-35. (Russian).</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B35">
    <label>35.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Bazin IS, Breder VV, Virshke ER, Gorbunova VA, Dolgushin BI, Kosyrev VYu, et al. Clinical recommendations for diagnosis and treatment of patients with liver cancer and extrahepatic bile ducts. All-Russian Union of Public Associations Association of Russian Oncologists, Moscow. 2014. (Russian).</mixed-citation>
     <mixed-citation xml:lang="en">Bazin IS, Breder VV, Virshke ER, Gorbunova VA, Dolgushin BI, Kosyrev VYu, et al. Clinical recommendations for diagnosis and treatment of patients with liver cancer and extrahepatic bile ducts. All-Russian Union of Public Associations Association of Russian Oncologists, Moscow. 2014. (Russian).</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B36">
    <label>36.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol. 1998;29:129-34.</mixed-citation>
     <mixed-citation xml:lang="en">Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol. 1998;29:129-34.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B37">
    <label>37.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Llovet JM, Real MI, Montana X, et al. Aterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-9.</mixed-citation>
     <mixed-citation xml:lang="en">Llovet JM, Real MI, Montana X, et al. Aterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-9.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B38">
    <label>38.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-71.</mixed-citation>
     <mixed-citation xml:lang="en">Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-71.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B39">
    <label>39.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Kasugai H, Kojima J, Tatsuta M, et al. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intrarterial infusion of a mixture of cisplatin and ethodised oil. Gastroenterology, 1989, 97:965-71.</mixed-citation>
     <mixed-citation xml:lang="en">Kasugai H, Kojima J, Tatsuta M, et al. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intrarterial infusion of a mixture of cisplatin and ethodised oil. Gastroenterology, 1989, 97:965-71.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B40">
    <label>40.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Ben-Josef E, Normolle D, Pan C, et al. Phase II trial of high dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2005;23:8739-47.</mixed-citation>
     <mixed-citation xml:lang="en">Ben-Josef E, Normolle D, Pan C, et al. Phase II trial of high dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2005;23:8739-47.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B41">
    <label>41.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Park W, Lim do H, Paik S.W, et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:1143-50.</mixed-citation>
     <mixed-citation xml:lang="en">Park W, Lim do H, Paik S.W, et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:1143-50.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B42">
    <label>42.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Dionisi F, Amichetti M. Proton Therapy Results in the Treatment of Hepatocellular Carcinoma According to the Barcelona-Clinic Liver Cancer (BCLC) Staging System. Int J Med Phys, Clin Eng  Radiat Oncol. 2015;4:96-103.</mixed-citation>
     <mixed-citation xml:lang="en">Dionisi F, Amichetti M. Proton Therapy Results in the Treatment of Hepatocellular Carcinoma According to the Barcelona-Clinic Liver Cancer (BCLC) Staging System. Int J Med Phys, Clin Eng  Radiat Oncol. 2015;4:96-103.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B43">
    <label>43.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of longterm outcomes. Gastroenterol. 2010;138:52-64.</mixed-citation>
     <mixed-citation xml:lang="en">Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of longterm outcomes. Gastroenterol. 2010;138:52-64.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B44">
    <label>44.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Sangro B, D’Avola D, Inarrairaegui M, Prieto J. Transarterial therapies for hepatocellular carcinoma. Expert Opin Pharmacother. 2011;12:1057-73.</mixed-citation>
     <mixed-citation xml:lang="en">Sangro B, D’Avola D, Inarrairaegui M, Prieto J. Transarterial therapies for hepatocellular carcinoma. Expert Opin Pharmacother. 2011;12:1057-73.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B45">
    <label>45.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Coldwell D, Sangro B, Wasan H, Salem R, Kennedy A. General selection criteria of patients for radioembolization of liver tumors: an International Working Group report. Am J Clin Oncol. 2011;34:337-41.</mixed-citation>
     <mixed-citation xml:lang="en">Coldwell D, Sangro B, Wasan H, Salem R, Kennedy A. General selection criteria of patients for radioembolization of liver tumors: an International Working Group report. Am J Clin Oncol. 2011;34:337-41.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B46">
    <label>46.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Lewandowski RJ, Sato KT, Atassi B, et al. Radioembolization with 90Y microspheres: Angiographic and technical consid erations. Cardiovasc Intervent Radiol. 2007;30(4):571-92.</mixed-citation>
     <mixed-citation xml:lang="en">Lewandowski RJ, Sato KT, Atassi B, et al. Radioembolization with 90Y microspheres: Angiographic and technical consid erations. Cardiovasc Intervent Radiol. 2007;30(4):571-92.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B47">
    <label>47.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: A state-of-the-art brachyterapy treatment foe primary and secondary liver malignancies: Part 1: Technical and methodologic considerations. J Vasc Interv Radiol. 2006;17:1251.</mixed-citation>
     <mixed-citation xml:lang="en">Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: A state-of-the-art brachyterapy treatment foe primary and secondary liver malignancies: Part 1: Technical and methodologic considerations. J Vasc Interv Radiol. 2006;17:1251.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B48">
    <label>48.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Drozdovskiy BYa, Petriev VM, Raziev PA, Goncharova AYa. Intraarterial selective therapy with cytostatic drugs and radiopharmaceuticals in malignant neoplasms (review). Oncology Issues, 1992;38(7):771-7.</mixed-citation>
     <mixed-citation xml:lang="en">Drozdovskiy BYa, Petriev VM, Raziev PA, Goncharova AYa. Intraarterial selective therapy with cytostatic drugs and radiopharmaceuticals in malignant neoplasms (review). Oncology Issues, 1992;38(7):771-7.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B49">
    <label>49.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Petriev VM, Smoryzanova OA, Skvortsov VG, et al. Pharmacokinetic characteristics of the radiopharmaceutical 188RE-albumin microspheres after intravenous administration to laboratory animals. Chem Pharm J. 2013;47(11):3-6.</mixed-citation>
     <mixed-citation xml:lang="en">Petriev VM, Smoryzanova OA, Skvortsov VG, et al. Pharmacokinetic characteristics of the radiopharmaceutical 188RE-albumin microspheres after intravenous administration to laboratory animals. Chem Pharm J. 2013;47(11):3-6.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B50">
    <label>50.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Nakakuma K, Tashiro S, Uemura K, et al. Studies on anticancer treatment with an oily anticancer drug injected into the ligated hepatic artery for hepatic cancer. Nichidoku Iho. 1979;24:675-82.</mixed-citation>
     <mixed-citation xml:lang="en">Nakakuma K, Tashiro S, Uemura K, et al. Studies on anticancer treatment with an oily anticancer drug injected into the ligated hepatic artery for hepatic cancer. Nichidoku Iho. 1979;24:675-82.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B51">
    <label>51.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">H. Ohishi, H. Uchida, H. Yoshimura et al. Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents. Radiology, 1985;154:25-9.</mixed-citation>
     <mixed-citation xml:lang="en">H. Ohishi, H. Uchida, H. Yoshimura et al. Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents. Radiology, 1985;154:25-9.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B52">
    <label>52.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Le Jeune JJ, Bourguet P, Victor G, et al. 131I-Lipiodol in the treatment of hepatocellular carcinoma: results of a multicenter phase II study of fifty patients. Eur J Nucl Med. 1990;16:143.</mixed-citation>
     <mixed-citation xml:lang="en">Le Jeune JJ, Bourguet P, Victor G, et al. 131I-Lipiodol in the treatment of hepatocellular carcinoma: results of a multicenter phase II study of fifty patients. Eur J Nucl Med. 1990;16:143.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B53">
    <label>53.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Raoul JL, Bourguet P, Bretagne JF, et al. Hepatic artery injection of 131I-labeled lipiodol. Part I. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases. Radiol. 1988. 168(2):541-5.</mixed-citation>
     <mixed-citation xml:lang="en">Raoul JL, Bourguet P, Bretagne JF, et al. Hepatic artery injection of 131I-labeled lipiodol. Part I. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases. Radiol. 1988. 168(2):541-5.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B54">
    <label>54.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Nakajo M, Kobayashi H, Shimabukuro K, et al. Biodistribution and in vivo kinetics of iodine-131 lipiodol infused via the hepatic artery of patients with hepatic cancer. J Nucl Med. 1988;29(6):1066-77.</mixed-citation>
     <mixed-citation xml:lang="en">Nakajo M, Kobayashi H, Shimabukuro K, et al. Biodistribution and in vivo kinetics of iodine-131 lipiodol infused via the hepatic artery of patients with hepatic cancer. J Nucl Med. 1988;29(6):1066-77.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B55">
    <label>55.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Raoul JI, Bretagne JF, Caucanas JP, et al. Internal radiation therapy for hepatocellular carcinoma. Results of a French multicenter phase II trial of transarterial injection of iodine 131-labeled Lipiodol. Cancer. 1992;69:346-52.</mixed-citation>
     <mixed-citation xml:lang="en">Raoul JI, Bretagne JF, Caucanas JP, et al. Internal radiation therapy for hepatocellular carcinoma. Results of a French multicenter phase II trial of transarterial injection of iodine 131-labeled Lipiodol. Cancer. 1992;69:346-52.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B56">
    <label>56.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Lambert B, Bacher K, Gemmel F, et al. 188Re-Lipiodol for locoregional treatment of hepatocellular carcinoma: a phase I study. Eur J Nucl Med. 2003;30(suppl. 2):219.</mixed-citation>
     <mixed-citation xml:lang="en">Lambert B, Bacher K, Gemmel F, et al. 188Re-Lipiodol for locoregional treatment of hepatocellular carcinoma: a phase I study. Eur J Nucl Med. 2003;30(suppl. 2):219.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B57">
    <label>57.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Bernal P, Osorio M, Gutierrez C, et al. Treatment of liver cancer with Rhenium-188 Lipiodol: Colombian Experience. Eur J Nucl Med. 2002;29(suppl. 1):180.</mixed-citation>
     <mixed-citation xml:lang="en">Bernal P, Osorio M, Gutierrez C, et al. Treatment of liver cancer with Rhenium-188 Lipiodol: Colombian Experience. Eur J Nucl Med. 2002;29(suppl. 1):180.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B58">
    <label>58.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Ruyck K De, Vral A, Lambert B, et al. Comparison of the cytotoxic effect of 131I-lipiodol therapy and 188Re-lipiodol therapy in hepatocellular cancer patients. Eur J Nucl Med. 2003;30(suppl. 2):343.</mixed-citation>
     <mixed-citation xml:lang="en">Ruyck K De, Vral A, Lambert B, et al. Comparison of the cytotoxic effect of 131I-lipiodol therapy and 188Re-lipiodol therapy in hepatocellular cancer patients. Eur J Nucl Med. 2003;30(suppl. 2):343.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B59">
    <label>59.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Kennedy AS, Kleinstreuer C, Basciano CA, Dezarn WA. Computer modeling of yttrium-90 microsphere transport in the hepatic arterial tree to improve clinical outcomes. Int J Radiat Oncol Biol Phys. 2010;76:631-7.</mixed-citation>
     <mixed-citation xml:lang="en">Kennedy AS, Kleinstreuer C, Basciano CA, Dezarn WA. Computer modeling of yttrium-90 microsphere transport in the hepatic arterial tree to improve clinical outcomes. Int J Radiat Oncol Biol Phys. 2010;76:631-7.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B60">
    <label>60.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Lau WY, Kennedy AS, Kim YH, Lai HK, Lee RC, Leung TW, et al. Patient selection and activity planning guide for selective internal radiotherapy with Yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys. 2010;76:643-9.</mixed-citation>
     <mixed-citation xml:lang="en">Lau WY, Kennedy AS, Kim YH, Lai HK, Lee RC, Leung TW, et al. Patient selection and activity planning guide for selective internal radiotherapy with Yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys. 2010;76:643-9.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B61">
    <label>61.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Gulec SA, Mesoloras G, Dezarn WA, McNeillie P, Kennedy AS. Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio. J Transl Med. 2007;5:15.</mixed-citation>
     <mixed-citation xml:lang="en">Gulec SA, Mesoloras G, Dezarn WA, McNeillie P, Kennedy AS. Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio. J Transl Med. 2007;5:15.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B62">
    <label>62.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Hilgard P, Hamami M, Fouly AE, Scherag A, Muller S, Ertle J, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52:1741-9.</mixed-citation>
     <mixed-citation xml:lang="en">Hilgard P, Hamami M, Fouly AE, Scherag A, Muller S, Ertle J, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52:1741-9.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B63">
    <label>63.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after (90) Y resin microsphere radioembolization of hepatocellular carcinoma across BCLC stages: a European evaluation. Hepatology. 2011;54:868-78</mixed-citation>
     <mixed-citation xml:lang="en">Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after (90) Y resin microsphere radioembolization of hepatocellular carcinoma across BCLC stages: a European evaluation. Hepatology. 2011;54:868-78</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B64">
    <label>64.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer. 2002;94:1747-52.</mixed-citation>
     <mixed-citation xml:lang="en">Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer. 2002;94:1747-52.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B65">
    <label>65.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys, 1995;33:919-24.</mixed-citation>
     <mixed-citation xml:lang="en">Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys, 1995;33:919-24.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B66">
    <label>66.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Furuse J, Ishii H, Nagase M, Kawashima M, Ogino T, Yoshino M. Adverse hepatic events caused by radiotherapy for advanced hepatocellular carcinoma. J Gastroenterol Hepatol. 2005;20:1512-8.</mixed-citation>
     <mixed-citation xml:lang="en">Furuse J, Ishii H, Nagase M, Kawashima M, Ogino T, Yoshino M. Adverse hepatic events caused by radiotherapy for advanced hepatocellular carcinoma. J Gastroenterol Hepatol. 2005;20:1512-8.</mixed-citation>
    </citation-alternatives>
   </ref>
  </ref-list>
 </back>
</article>
